[go: up one dir, main page]

NZ511034A - Methods of downmodulating the immune response to therapeutic proteins - Google Patents

Methods of downmodulating the immune response to therapeutic proteins

Info

Publication number
NZ511034A
NZ511034A NZ511034A NZ51103499A NZ511034A NZ 511034 A NZ511034 A NZ 511034A NZ 511034 A NZ511034 A NZ 511034A NZ 51103499 A NZ51103499 A NZ 51103499A NZ 511034 A NZ511034 A NZ 511034A
Authority
NZ
New Zealand
Prior art keywords
immune response
downmodulating
methods
therapeutic proteins
composition
Prior art date
Application number
NZ511034A
Inventor
Jiahua Qian
Leon W Hoyer
Mary Collins
Gary Gray
Original Assignee
American Nat Red Cross
Inst Genetics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Nat Red Cross, Inst Genetics Llc filed Critical American Nat Red Cross
Publication of NZ511034A publication Critical patent/NZ511034A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A composition comprising a therapeutic protein, such as factor VIII, which promotes hemostasis and an agent, such as CTLA4, which inhibits the interaction of a costimulatory molecule on an antigen presenting cell and its cognate ligand on a T cell, wherein said composition is a composition for the treatment of a hemostatic disorder which reduces the development and/or progression of an immune response to the therapeutic protein.
NZ511034A 1998-09-21 1999-09-21 Methods of downmodulating the immune response to therapeutic proteins NZ511034A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15817898A 1998-09-21 1998-09-21
PCT/US1999/021991 WO2000016801A1 (en) 1998-09-21 1999-09-21 Methods of downmodulating the immune response to therapeutic proteins

Publications (1)

Publication Number Publication Date
NZ511034A true NZ511034A (en) 2004-03-26

Family

ID=22566971

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ511034A NZ511034A (en) 1998-09-21 1999-09-21 Methods of downmodulating the immune response to therapeutic proteins

Country Status (21)

Country Link
EP (1) EP1115423A1 (en)
JP (1) JP2002526455A (en)
KR (1) KR20010085830A (en)
CN (1) CN1331602A (en)
AU (1) AU761206B2 (en)
BR (1) BR9913991A (en)
CA (1) CA2343916A1 (en)
CZ (1) CZ20011021A3 (en)
EA (1) EA005236B1 (en)
HK (1) HK1039059A1 (en)
HU (1) HUP0103960A3 (en)
IL (1) IL142069A0 (en)
LT (1) LT4920B (en)
LV (1) LV12768B (en)
MX (1) MXPA01002898A (en)
NO (1) NO20011412L (en)
NZ (1) NZ511034A (en)
PL (1) PL346796A1 (en)
SI (1) SI20626A (en)
WO (1) WO2000016801A1 (en)
ZA (1) ZA200103156B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
AU2001261735B2 (en) * 2000-05-19 2006-09-21 The Center For Blood Research, Inc. Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
EP1636579A4 (en) * 2003-06-10 2011-10-05 Smiths Detection Inc Sensor arrangement
GB201508024D0 (en) * 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
MX9203440A (en) 1985-04-12 1992-07-01 Genetics Inst NOVEL PROCOAGULANT PROTEINS.
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
FR2657884B1 (en) 1990-02-05 1994-09-02 Tm Innovation PROCESS FOR THE PREPARATION OF HUMAN FACTOR VIII AND FACTOR VIII ANALOGS.
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
DE122007000078I2 (en) 1991-06-27 2011-01-13 Bristol Myers Squibb Co CTL4A receptor, fusion proteins containing it and their use
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
WO1993009804A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
EP0776217A1 (en) * 1994-08-19 1997-06-04 Novo Nordisk A/S A method of treating a patient with a biologically active compound
CA2200869A1 (en) * 1994-10-19 1996-05-02 Bruce C. Trapnell Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
WO1997034633A1 (en) * 1996-03-20 1997-09-25 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
CZ244399A3 (en) * 1997-01-10 1999-10-13 Biogen, Inc. The use of an anti-CD40L compound for the manufacture of a medicament for the treatment of immunological diseases
IL133305A0 (en) * 1997-06-20 2001-04-30 Biogen Inc Use of a cd40:cd154 binding interruptor for treating protein inhibitor syndrome
US8112896B2 (en) 2009-11-06 2012-02-14 Hexagon Metrology Ab Articulated arm

Also Published As

Publication number Publication date
EA200100385A1 (en) 2001-10-22
HK1039059A1 (en) 2002-04-12
CA2343916A1 (en) 2000-03-30
MXPA01002898A (en) 2002-06-04
EP1115423A1 (en) 2001-07-18
HUP0103960A2 (en) 2002-02-28
SI20626A (en) 2002-02-28
LT2001045A (en) 2002-01-25
LV12768B (en) 2002-06-20
LT4920B (en) 2002-06-25
IL142069A0 (en) 2002-03-10
BR9913991A (en) 2001-07-03
ZA200103156B (en) 2002-07-18
AU6057899A (en) 2000-04-10
KR20010085830A (en) 2001-09-07
CZ20011021A3 (en) 2001-10-17
JP2002526455A (en) 2002-08-20
NO20011412L (en) 2001-05-16
LV12768A (en) 2001-12-20
PL346796A1 (en) 2002-02-25
AU761206B2 (en) 2003-05-29
CN1331602A (en) 2002-01-16
NO20011412D0 (en) 2001-03-20
HUP0103960A3 (en) 2003-09-29
WO2000016801A9 (en) 2000-10-26
WO2000016801A1 (en) 2000-03-30
EA005236B1 (en) 2004-12-30

Similar Documents

Publication Publication Date Title
DK0643726T3 (en) Human p53 protein peptides for use in compositions that induce human T cell response and human p53 protein
FI953442A0 (en) Freeze-dried beads containing gonadotropin
TR199903331T2 (en) Farnesil protein transferase inhibitors.
EP0724456A4 (en) ANTIBODIES DIRECTED AGAINST CD40
ATE517922T1 (en) STABILIZED SINGLE-DOMAIN ANTIBODIES IN A PHARMACEUTICAL COMPOSITION DESIGNED FOR INHALATION
FI961621A0 (en) Substituted tetra- and pentapeptide inhibitors of protein: farnesyl transferase
CY1111863T1 (en) OPTIONS AGAINST DEATH RECEPTOR 4 (DR4) AND THEIR USES
WO1998022136A3 (en) Stable lyophilized pharmaceutical substances from monoclonal or polyclonal antibodies
UA95438C2 (en) Bispecific antibodies substituting for functional proteins
IS2505B (en) Reflective contrast agents, preferably long in the blood, for diagnostic purposes
IL160641A0 (en) Carbohydrate binding domain containing fusion proteins for delivery of therapeutic and other agents, and compositions containing them
IL127558A0 (en) Hepatocyte growth factor receptor agonists and uses thereof
CA2413190A1 (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
DK0836485T3 (en) Cascade-polymer complexes, processes for their preparation, and pharmaceutical agents containing them
DK0915974T3 (en) Modified tie-2 receptor ligands
CY1109868T1 (en) CD81 PROFESSIONAL SUBSCRIPTION PROTECTOR C
DK0845998T3 (en) Immunotherapy drugs containing antibodies that specifically recognize the MHCII antigen in a patient to be treated
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
DE69434384D1 (en) METALKOMPLEXBILDNER
AU6832398A (en) Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
ATE234111T1 (en) THERAPEUTIC USES OF BPI PROTEIN PRODUCTS IN PEOPLE WITH BLEEDING CAUSED BY TRAUMA
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
MX9101958A (en) AMINOSULFONYL UREA ACAT INHIBITORS
NZ511034A (en) Methods of downmodulating the immune response to therapeutic proteins
KR950702207A (en) Antigenic sites for TLP complexes and antibodies there (ANTIGENIC REGIONS OF TUMOUR-LIBERATED PARTICLES (TLP) COMPLEXES AND ANTIBODIES AGAINST THEM)

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: AMERICAN RED CROSS, US

Free format text: OLD OWNER(S): AMERICAN RED CROSS; GENETICS INSTITUTE, INC.

Owner name: GENETICS INSTITUTE, US

Free format text: OLD OWNER(S): AMERICAN RED CROSS; GENETICS INSTITUTE, INC.

PSEA Patent sealed
RENW Renewal (renewal fees accepted)